Contribute Try STAT+ Today

They may be unparalleled lifesavers. Or they may be keeping lifesaving drugs off the market.

For more than three hours on Monday, FDA officials heard dramatically different forecasts for the future of fecal matter transplants, a relatively new therapy that is mostly used to treat recurrent Clostridium difficile infections. The meeting happened less than a week after a paper in the New England Journal of Medicine revealed new details about the first-ever death associated with the procedure.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.